2014
DOI: 10.3791/51309
|View full text |Cite
|
Sign up to set email alerts
|

Analysis of RNA Processing Reactions Using Cell Free Systems: 3' End Cleavage of Pre-mRNA Substrates <em>in vitro</em>

Abstract: The 3’ end of mammalian mRNAs is not formed by abrupt termination of transcription by RNA polymerase II (RNPII). Instead, RNPII synthesizes precursor mRNA beyond the end of mature RNAs, and an active process of endonuclease activity is required at a specific site. Cleavage of the precursor RNA normally occurs 10–30 nt downstream from the consensus polyA site (AAUAAA) after the CA dinucleotides. Proteins from the cleavage complex, a multifactorial protein complex of approximately 800kDa, accomplish this specifi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2016
2016
2016
2016

Publication Types

Select...
1

Relationship

1
0

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 26 publications
(18 reference statements)
0
2
0
Order By: Relevance
“…In vitro pre-mRNA 3′ cleavage reactions were carried out as previously described [22,33,35]. The total reaction volume was 12.5 μl and in place of nuclear extract the following DEAE-fractionated cleavage factors (~2–4 mg/ml total protein each) were included: 0.9 μl of CPSF, 0.45 μl of CstF, 1.8 μl of CF m .…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…In vitro pre-mRNA 3′ cleavage reactions were carried out as previously described [22,33,35]. The total reaction volume was 12.5 μl and in place of nuclear extract the following DEAE-fractionated cleavage factors (~2–4 mg/ml total protein each) were included: 0.9 μl of CPSF, 0.45 μl of CstF, 1.8 μl of CF m .…”
Section: Methodsmentioning
confidence: 99%
“…In vitro cleavage was carried out in 12.5 μl at 30 °C for 2 h as described [22,33,35]. The final reaction component concentrations were: 1.25 μg of tRNA, 1.6 mM DTT, 50 mM CP, 6 u of recombinant RNase Inhibitor (Promega), 2.5% PVA, 2 mM EDTA, 3 nM 32 P-labeled L3 substrate, 5 μl of CSF, and PAP and ATP as indicated in Fig.…”
Section: Methodsmentioning
confidence: 99%